Claims for Patent: 10,357,616

Summary for Patent: 10,357,616

Title:	Injection device with an end of dose feedback mechanism
Abstract:	An injection device with a dose delivering mechanism being adapted to provide a non-visual, e.g. audible and/or tactile, feedback signal when a set dose has been at least substantially injected. A first and a second part of the injection device are adapted to perform a relative rotational movement with respect to each other. The relative rotational movement causes at least two parts of the injection device to abut or engage, and this abutment or engagement causes the non-visual feedback signal to be generated. A very distinct and precise feedback is provided as compared to prior art axial solutions because the generation of the feedback signal is initiated by the relative rotational movement.
Inventor(s):	Moller Claus Schmidt, Radmer Bo, Nielsen Lars Ulrik, Enggaard Christian Peter
Assignee:	Novo Nordisk A/S
Application Number:	US15815976
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,357,616
Patent Claims:

Details for Patent 10,357,616

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536	June 16, 2005		2037-11-17
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536	October 31, 2013		2037-11-17
Novo Nordisk Inc.	TRESIBA	insulin degludec	Injection	203314	September 25, 2015		2037-11-17
Novo Nordisk Inc.	TRESIBA	insulin degludec	Injection	203314	November 21, 2018		2037-11-17
Novo Nordisk Inc.	FIASP	insulin aspart	Injection	208751	September 29, 2017		2037-11-17
Novo Nordisk Inc.	FIASP	insulin aspart	Injection	208751	September 24, 2018		2037-11-17
Novo Nordisk Inc.	FIASP	insulin aspart	Injection	208751	June 21, 2023		2037-11-17